Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity

Mona Meyer, Jüri Reimand, Xiaoyang Lan, Renee Head, Xueming Zhu, Michelle Kushida, Jane Bayani, Jessica C. Pressey, Anath C. Lionel, Ian D. Clarke, Michael D. Cusimano, Jeremy A. Squire, Stephen W. Scherer, Mark Bernstein, Melanie A. Woodin, Gary D. Bader, Peter B. DirksProceedings of the National Academy of Sciences 2015 · DOI

TL;DR

This paper tackles the challenge of glioblastoma's extreme heterogeneity by developing a method to isolate and functionally profile individual tumor clones. They discovered that drug resistance can pre-exist within tumors at a clonal level, paving the way for clone-specific therapeutic strategies.

What Problem Does This Paper Address?

Glioblastoma (GBM) is a notoriously aggressive brain cancer characterized by a high degree of diversity among its cells, both in appearance (morphology) and genetic makeup. This "intratumoral heterogeneity" is a major hurdle in developing effective treatments, as a therapy that works on one type of GBM cell might be completely ineffective against another. While genomic studies have revealed subtypes of GBM, the functional consequences of this heterogeneity – particularly in terms of treatment resistance and tumor progression – remain poorly understood. The paper aims to bridge this gap by directly linking the functional behavior of individual GBM clones to their underlying genomic profiles.

Methods

The core innovation here is a method to isolate and analyze individual, single cell-derived clones from patient GBM samples. This involves:

  • Single Cell Isolation and Expansion: Using fluorescence-activated cell sorting (FACS) to isolate individual cells from tumor samples, followed by expansion in stem cell media to generate clonal populations.
  • Functional Profiling: Assessing key functional characteristics of these clones, including their tumorigenicity (ability to form tumors in vivo), proliferation rates, and differentiation potential. Crucially, they also tested clonal responses to the standard GBM chemotherapy agent, temozolomide (TMZ), and screened a library of 98 drugs for clone-specific sensitivities.
  • Genomic Analysis: Performing copy number (CN) profiling and gene expression analysis (microarrays) on these isolated clones to identify genetic alterations and transcriptional differences.
  • Integrated Analysis: Combining the functional and genomic data to identify correlations between specific genetic profiles and observed functional behaviors, such as drug resistance.

Datasets

The study utilized samples from four individual patients with glioblastoma. They generated 44 single cell-derived clones from these tumors.

Key Insights and Ideas

  • Pre-existing Drug Resistance: Perhaps the most significant finding is that resistance to temozolomide (TMZ), the standard chemotherapy for GBM, can exist before treatment even begins, at the clonal level. This means that some tumor cells are inherently resistant, explaining why many patients don't respond to therapy and why tumors often relapse.
  • Functional Diversity Within a Single Tumor: Even clones derived from the same patient's tumor exhibit distinct abilities in terms of proliferation, differentiation, and drug response. This highlights that a single tumor is a complex ecosystem of functionally different cell populations.
  • Genomics Predicts Function (to an extent): The study found correlations between specific genomic alterations (like copy number variations) and gene expression patterns with observed functional behaviors. This suggests that understanding the genetic landscape of individual clones can provide clues about their behavior.
  • Clone-Specific Therapies are Feasible: The drug screening revealed that different clones within the same tumor can have vastly different sensitivities to various drugs. This opens the door to developing personalized, clone-specific treatment strategies, rather than a one-size-fits-all approach.

Key Results

  • 44 single cell-derived clones were generated from four patient GBM samples, all of which formed tumors in mice, confirming their tumorigenic potential.
  • Individual clones showed significant variation in proliferation and differentiation abilities.
  • Importantly, in two out of four tumors, clones exhibiting significant resistance to temozolomide (TMZ) were identified in naïve (untreated) samples.
  • A screen of 98 drugs revealed clone-by-clone variability in drug responses, suggesting potential for targeted therapies.
  • Genomic analysis identified copy number alterations in 456 genes and revealed that transcriptional profiles of clones from the same tumor were generally similar, but with notable exceptions, such as a TMZ-sensitive clone being transcriptionally distinct from its resistant counterparts.
  • Pathway analysis of the TMZ-sensitive clone highlighted differential expression in pathways related to cell migration, angiogenesis, and neurotransmitter signaling, suggesting these pathways might be targets for overcoming resistance.

Limitations and Future Work

  • Limited Sample Size: While the study generated a significant number of clones, it was based on only four patient tumors. Larger studies are needed to confirm these findings across a broader patient population.
  • Capturing All Clones: The authors acknowledge that their method might not capture all relevant clones present in a primary tumor, especially very rare ones.
  • Future Directions: The authors strongly advocate for the continued development and application of clone-specific functional profiling. They predict that this approach will be crucial for identifying aggressive, relapse-initiating clones, discovering new cancer driver mechanisms, and developing novel, clone-specific therapeutic strategies for GBM and potentially other cancers. They also suggest that integrating deep sequencing with computational inference of clonal structure will be valuable.

Summary updated

Abstract

Glioblastoma (GBM) is a cancer comprised of morphologically, genetically, and phenotypically diverse cells. However, an understanding of the functional significance of intratumoral heterogeneity is lacking. We devised a method to isolate and functionally profile tumorigenic clones from patient glioblastoma samples. Individual clones demonstrated unique proliferation and differentiation abilities. Importantly, naïve patient tumors included clones that were temozolomide resistant, indicating that resistance to conventional GBM therapy can preexist in untreated tumors at a clonal level. Further, candidate therapies for resistant clones were detected with clone-specific drug screening. Genomic analyses revealed genes and pathways that associate with specific functional behavior of single clones. Our results suggest that functional clonal profiling used to identify tumorigenic and drug-resistant tumor clones will lead to the discovery of new GBM clone-specific treatment strategies.
BibTeX
@inproceedings{meyer2015single,
  author = {Mona Meyer and Jüri Reimand and Xiaoyang Lan and Renee Head and Xueming Zhu and Michelle Kushida and Jane Bayani and Jessica C. Pressey and Anath C. Lionel and Ian D. Clarke and Michael D. Cusimano and Jeremy A. Squire and Stephen W. Scherer and Mark Bernstein and Melanie A. Woodin and Gary D. Bader and Peter B. Dirks},
  title = {{Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2015},
  doi = {10.1073/pnas.1320611111},
}
Figure